Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Paul G. Long"'
Publikováno v:
Expert Review of Anti-infective Therapy. 21:235-242
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f03bb20a6c35ed142847acf99ab0116
https://doi.org/10.1080/14787210.2023.2170350
https://doi.org/10.1080/14787210.2023.2170350
Autor:
Douglas W. Grosenbach, Paul G Long, Dennis E. Hruby, Andrew T. Russo, Candace Lovejoy, Ingrid Meara, Biswajit Maiti, Kady M. Honeychurch, Jarasvech Chinsangaram
Publikováno v:
Expert Review of Anti-infective Therapy. 19:331-344
Tecovirimat (TPOXX®; ST-246) was approved for the treatment of symptomatic smallpox by the USFDA in July of 2018 and has been stockpiled by the US government for use in a smallpox outbreak. While there has not been a reported case of smallpox since
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03dc2def56381c858bab7f5fa34ac3a6
https://doi.org/10.1080/14787210.2020.1819791
https://doi.org/10.1080/14787210.2020.1819791
Autor:
Dennis E. Hruby, Paul G Long, Jarasvech Chinsangaram, Annie Frimm, Candace Lovejoy, Biswajit Maiti, Eric A. Rose, Ingrid Meara, Kady M. Honeychurch, Douglas W. Grosenbach
Publikováno v:
The New England journal of medicine
Smallpox was declared eradicated in 1980, but variola virus (VARV), which causes smallpox, still exists. There is no known effective treatment for smallpox; therefore, tecovirimat is being developed as an oral smallpox therapy. Because clinical trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfebb26a63f3288d5bbc8826fcabdf7f
https://hdl.handle.net/10067/1714920151162165141
https://hdl.handle.net/10067/1714920151162165141